Fréderic Duprez

Fréderic Duprez

Auto-generated profile, based on publicly available information

Fréderic Duprez

Department of Human Structure and Repair Ghent University Ghent Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2018 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
JSJulie Schatteman
Julie Schatteman
DGDirk Van Gestel
Dirk Van Gestel
DBDieter Berwouts
Dieter Berwouts
WGWerner De Gersem
Werner De Gersem
GKGeert De Kerf
Geert De Kerf
FDFréderic Duprez
Fréderic Duprez


16 January 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
Tijl VermassenTijl Vermassen
Tijl Vermassen
SKStijn De Keukeleire
Stijn De Keukeleire
MSMichael Saerens
Michael Saerens
SHSylvester Heerwegh
Sylvester Heerwegh
JDJens Debacker
Jens Debacker
TZThibaut Van Zele
Thibaut Van Zele

23 June 2019 in Acta Clinica Belgica
Verified
Journal Article
Closed access
KCKaren Couvreur
Karen Couvreur
CJCeline Jacobs
Celine Jacobs
BMBock Marlies
Bock Marlies
DRD’hondt Randal
D’hondt Randal
DPDeron Philippe
Deron Philippe
RSRottey Sylvie
Rottey Sylvie
Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare malignancy of the salivary glands that accounts for approximately 10% of salivary gland carcinoma. Despite aggressive local therapy, local recurrence and distant metastases occur frequently. Response rates (RR) to potential curative and palliative chemotherapy are limited, so new strategies are needed. Case reports: We describe five case reports of patients with unresectable locally advanced or metastatic ACC of the head and neck who have been treated with sorafenib, a multi-tyrosine kinase inhibitor (mTKI). Results: In this case series, we found that three out of five patients treated with sorafenib survived, respectively, 16, 35 and 35 months. Two patients showed a partial response (PR) and one patient had a prolonged stable disease (SD) for almost three years. Grade 3 adverse events (AE) occur under sorafenib so adequate toxicity management is essential. This retrospective case series hints towards the possibility of clinical benefit for treating ACC patients with sorafenib. Efficacy of sorafenib should be studied in a prospective-randomized clinical trial which is a challenging task due to the rarity of the disease.

11 April 2020 in Acta Clinica Belgica
Verified
Journal Article
Closed access
SKStijn De Keukeleire
Stijn De Keukeleire
AMAstrid De Meulenaere
Astrid De Meulenaere
PDPhilippe Deron
Philippe Deron
WHWouter Huvenne
Wouter Huvenne
DFDuprez Fréderic
Duprez Fréderic
SRSylvie Rottey
Sylvie Rottey
Background and aim: Verrucous hyperplasia (VH) and verrucous carcinoma (VC) of the head and neck are two (pre)malignant entities that are slowly progressive with low tendency to metastasize. However, they can reduce the patient’s Quality of Life (QoL) and may even transform into squamous cell carcinoma (SCC). As they are typically approached by surgical resection, some patients do not qualify for surgery. Methotrexate may be a systemic alternative but the response is mostly not durable. This case report tries to illustrate the potential role of methotrexate in VH/VC of the head and neck. Method: We describe four cases of patients with VH or VC of the head and neck who received methotrexate (40–60 mg/m2) in a weekly or two-weekly interval. Results: Two patients received methotrexate in a neoadjuvant setting. The first patient achieved a macroscopical complete response after 16 cycles and remained in remission after surgery. The second patient suffered from residual disease after 26 cycles and refused radical surgery. Two other patients refused surgery at the time of diagnosis and were proposed methotrexate as a salvage treatment. The first patient had an ongoing response on methotrexate after >60 cycles. The second patient achieved macroscopical complete remission after 28 cycles of methotrexate but suffered relapse by developing an oropharyngeal SCC in the same region. Conclusion: When surgery is not desirable in VH and/or VC, patients can be treated with methotrexate which has a reasonable effect and seems to be well tolerated. Nevertheless, surgery should be the preferred strategy to achieve complete remission.

20 December 2025 in Head & Neck
Verified
Journal Article
Closed access
HMHanne Massonet
Hanne Massonet
AGAnn Goeleven
Ann Goeleven
Sandra NuytsSandra Nuyts
Sandra Nuyts
AVAlice Vergauwen
Alice Vergauwen
MBMargot Baudelet
Margot Baudelet
GNGwen Van Nuffelen
Gwen Van Nuffelen